Facebook
Twitter
LinkedIn
Forward
At the Cutting Edge: The Increasing Role of Salvage Radiotherapy in Relapsed/Refractory Lymphomas
Recently, there have been exciting advances in the treatment of relapsed/refractory (R/R) lymphomas. Historically, the standard-of-care included salvage chemotherapy followed by autologous stem cell transplantation (ASCT). Today, many other salvage options are available. Radiation therapy (RT) can be a useful adjunct to improve the efficacy and/or limit the toxicity of salvage strategies. For example, appropriately selected patients with relapsed Hodgkin lymphoma experience outstanding disease control with novel systemic therapies combined with RT. This combined modality approach allows patients to avoid the toxicities associated with ASCT. Second, in patients with R/R diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR)-T cell therapy has revolutionized treatment. The incorporation of RT with CAR-T cell therapy may improve patient outcomes. Lastly, RT alone can result in outstanding disease control in patients with a partial metabolic response to upfront chemotherapy. With the appropriate use of RT, these patients may avoid intensive systemic salvage therapies.
Topics:
- Radiotherapy in Combination with Novel Systemic Agents for Transplant-Free Salvage of Relapsed Hodgkin Lymphoma
Bradford Hoppe, MD, FASTRO, MPH - Radiotherapy’s Effective Incorporation with Chimeric Antigen Receptor (CAR) T-cell Therapy for Relapsed/Refractory DLBCL
Timothy J. Robinson, MD, PhD - Excellent Outcomes with Radiotherapy Alone After a Partial Metabolic Response of Lymphomas to Frontline Systemic Therapy
Andrea Ng, MD, FASTRO, MPH - Q and A
Full Panel
This activity is available from January 7, 2025, through 11:59 p.m. Eastern time on January 6, 2027.
This activity was originally recorded at the 2024 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, diagnostic radiologists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the role of radiotherapy in transplant-free salvage of relapsed Hodgkin lymphoma.
- Identify patients for whom radiotherapy may be beneficial before or after chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory DLBCL.
- Determine when radiotherapy alone should be used to treat lymphomas with an incomplete metabolic response to frontline systemic therapy.
- Sarah A. Milgrom, MD, is employed by University of Colorado. Dr. Milgrom serves in an uncompensated role as a consultant for Bristol Myers Squibb. Dr. Milgrom is Vice Chair of the Appropriate Use Criteria Lymphoma Committee of the American Radium Society.
- Bradford S. Hoppe, MD, FASTRO, MPH, is employed by Mayo Clinic. Dr. Hoppe serves on the advisory board of Merck. Dr. Hoppe is secretary of the Particle Therapy Cooperative Group (PTCOG) and Co-chair of the NRG lymphoma working group.
- Timothy John Robinson, MD, PhD, is employed by Yale University. Dr. Robinson receives honoraria from Kite Pharma. Dr. Robinson owns patents with Duke University and H. Lee Moffitt Cancer Center.
- Andrea K. Ng, MD, FASTRO, MPH, is employed by Dana-Farber Cancer Institute and Brigham and Women’s Hospital. Dr. Ng receives a publishing royalty from UpToDate. Dr. Ng serves as a Trustee with the American Board of Radiology.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until January 6, 2027, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.